MEREO BIOPHARMA GROUP PLC (MREO) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -34.20M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | |
| Cost of products and services | (m) | |
| Research and development | 15.02M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-34.20M | $0.00 | (m) | $15.02M | (m) | (m) |
| 2026-03-31 | $-37.67M | (m) | (m) | $18.58M | (m) | (m) |
| 2025-12-31 | $-40.11M | $500.00K | (m) | $17.77M | (m) | -8021.40% |
| 2025-09-30 | $-46.99M | $500.00K | (m) | $22.39M | (m) | -9398.40% |
| 2025-06-30 | $-46.35M | $500.00K | (m) | $21.29M | (m) | -9269.80% |
| 2025-03-31 | $-48.67M | (m) | (m) | $20.87M | (m) | (m) |
| 2024-12-31 | $-47.36M | $0.00 | (m) | $20.93M | (m) | (m) |
| 2024-09-30 | $-39.22M | $1.00M | (m) | $16.91M | (m) | -3921.70% |
| 2024-06-30 | $-38.91M | $1.00M | (m) | $17.34M | (m) | -3891.10% |
| 2024-03-31 | $-26.91M | $10.00M | (m) | $16.11M | (m) | -269.06% |
| 2023-12-31 | $-28.42M | $10.00M | (m) | $17.42M | (m) | -284.16% |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-54.43M | $0.00 | (m) | $29.46M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |